Please use this identifier to cite or link to this item: https://repositorio.usj.es/handle/123456789/708

Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarrón, Servando E.-
dc.contributor.authorTomás-Aragonés, Lucía-
dc.contributor.authorMoncin-Torres, Carlos A.-
dc.contributor.authorGómez Barrera, Manuel-
dc.contributor.authorGarcía-Latasa de Araníbar, Francisco Javier-
dc.date.accessioned2021-11-24T16:07:49Z-
dc.date.available2021-11-24T16:07:49Z-
dc.date.issued2021-06-25-
dc.identifier.citationMarron, S.E.; Tomas-Aragones, L.; Moncin-Torres, C.A.; Gomez-Barrera, M.; Aranibar, F.J.G.-L.d. Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. Life 2021, 11, 617. https://doi.org/10.3390/life11070617es_ES
dc.identifier.issn2075-1729es_ES
dc.identifier.urihttps://repositorio.usj.es/handle/123456789/708-
dc.description.abstractDupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. The outcomes were evaluated and registered at baseline and weeks 16, 40 and 52. The variables evaluated were: disease severity, pruritus, stressful life events, difficulty to sleep, anxiety and depression, quality of life, satisfaction, adherence to the treatment, efficacy and safety. Eleven patients were recruited between 14 Nov 2017 and 16 Jan 2018. Demographic variables: 90% Caucasian, 82% women. Clinical variables: Mean duration of AD = 17.7 (±12.8), 91% had severe disease severity. At baseline, SCORAD median (range) score = 69.2 (34.8–89.2); itch was reported by 100% of patients; itch visual analogue scale median (range) was 9 (6–10); HADS median (range) total score = 13 (5–21); DLQI mean score = 16 (2–27); EQ-5D-3L median (range) = 57 (30–99). At week- 52 there was a significant reduction of SCORAD scores median (range) = 4.3 (0–17.1), HADS total score median (range) = 2 (0–10) and improved quality of life EQ-5D-3L median (range) = 89 (92–60). This study confirms that dupilumab, used for 52-weeks under routine clinical practice, maintains the improved atopic dermatitis signs and symptoms obtained at week 16, with a good safety profile.es_ES
dc.format.extent14es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.requiresAdobees_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAtopic dermatitises_ES
dc.subjectPatient reported outcome measureses_ES
dc.subjectDupilumabes_ES
dc.subjectQuality of lifees_ES
dc.subjectSatisfactiones_ES
dc.subjectEfficacyes_ES
dc.subjectSafetyes_ES
dc.subjectAdherencees_ES
dc.titlePatient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Resultses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://www.mdpi.com/2075-1729/11/7/617es_ES
dc.identifier.publicationfirstpage1es_ES
dc.identifier.publicationlastpage14es_ES
dc.identifier.doi10.3390/life11070617es_ES
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses_ES
Appears in Collections:Artículos de revistas



This item is licensed under a Creative Commons License Creative Commons